<p><strong>杰克·本德海姆将担任执行董事长；丹尼尔·本德海姆被任命为首席执行官和总裁</strong></p>
<p>新泽西州提安克 --（商业新闻）-- 菲博动物健康公司（Nasdaq: PAHC）（“公司” 或 “菲博”）今天宣布了一项领导层变更，以支持公司的持续增长和长期战略方向。在本财年结束时，即 2026 年 7 月 1 日，现任菲博董事长、首席执行官和总裁的杰克·本德海姆将担任新的管理角色，成为执行董事长，而丹尼尔（丹尼）·本德海姆将担任菲博的首席执行官和总裁。杰克·本德海姆将继续担任公司董事会主席。</p>
<p>杰克·本德海姆于 1969 年加入公司，担任过多个管理和执行职位。自 1988 年以来，他一直担任公司的总裁，并于 2014 年 3 月被任命为首席执行官。他引导公司经历了重大的全球扩张、产品组合增长和运营转型。在他的领导下，菲博已成为动物健康行业的领导者之一，并巩固了其作为动物健康和营养领域值得信赖的合作伙伴的地位，为全球的畜牧生产者和客户提供服务。</p>
<p>“随着菲博的不断发展和扩展，现在是过渡领导层以引导公司进入下一个篇章的合适时机，” 杰克·本德海姆说。“丹尼对我们的业务有深刻的了解，具备强大的运营纪律和全球视野，这与我们行业的未来相一致。我对他能够引领菲博向前发展，同时保持我们几十年来定义公司的价值观、关系和对动物健康的承诺充满信心。”</p>
<p>公司的完整执行领导团队将继续留任，公司的董事会已表示对这一过渡的全力支持，并对领导团队执行公司增长战略的能力充满信心。</p>
<p>在担任执行董事长的新角色中，杰克·本德海姆将继续提供战略监督，支持菲博的长期增长计划，并与执行领导团队密切合作。</p>
<p>丹尼·本德海姆于 1997 年加入菲博，并于 2001 年被任命为业务发展副总裁，2004 年成为性能产品总裁，并于 2014 年 3 月担任企业战略执行副总裁。最近，他担任公司的首席转型官，负责菲博前进计划——一个专注于推动效率、增长和文化参与的企业范围内的项目，在公司最近的增长中发挥了关键作用。丹尼·本德海姆在菲博的全球运营中拥有丰富的经验，并在公司内有着良好的领导记录，他的任命反映了菲博的有序接班计划及其对连续性、创新和增长的承诺。</p>
<p>“我很荣幸能担任这个角色，并对我父亲几十年的领导和指导心怀感激，” 丹尼·本德海姆说。“菲博正处于历史上最好的位置，是一家以客户为中心的公司，拥有强大的基础和对创新的承诺。我期待继续与我们的全球领导团队以及我们在世界各地的敬业员工合作，推进我们的战略，支持我们的客户，并在公司的发展势头上继续前进。”</p>
<p><strong>关于菲博动物健康公司</strong></p>
<p>菲博动物健康公司是一家领先的全球多元化动物健康和营养公司。我们努力成为与畜牧生产者、农民、兽医和养殖或照顾农场和伴侣动物的消费者之间值得信赖的合作伙伴，提供解决方案以帮助他们维护和增强动物的健康。有关更多信息，请访问 www.pahc.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>披露通知</p>
<p>前瞻性声明：本通讯包含前瞻性声明，这些声明受到风险和不确定性的影响。所有除历史或当前事实声明以外的声明均为前瞻性声明。前瞻性声明讨论了我们对财务状况、运营结果、计划、目标、未来表现和业务的当前期望和预测。您可以通过这些声明与历史或当前事实无关来识别前瞻性声明。这些声明可能包括诸如 “目标”、“预期”、“相信”、“估计”、“期望”、“预测”、“展望”、“潜力”、“项目”、“计划”、“打算”、“寻求”、“可能”、“可以”、“将”、“应该”、“能够”、“可能” 等词语及其否定形式，以及与未来运营或财务表现或其他事件的时间或性质相关的任何讨论中的其他类似词语和术语。这些声明并不保证未来的表现或行动。如果这些风险或不确定性中的一个或多个实现，或者管理层的基本假设被证明是错误的，实际结果可能与前瞻性声明所设想的有重大差异。前瞻性声明仅在作出声明的日期有效。菲博明确声明不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。有关风险、不确定性和其他事项的进一步列表和描述可以在我们的 10-Q 季度报告和 10-K 年度报告中找到，包括其中标题为 “前瞻性声明” 和 “风险因素” 的部分。这些文件及后续文件可在 www.sec.gov、www.pahc.com 在线获取，或应菲博的要求提供。</p>
<p>信息的互联网发布：我们定期在我们的网站 www.pahc.com 的 “投资者” 部分发布可能对投资者重要的信息。我们鼓励投资者和潜在投资者定期查阅我们的网站，以获取有关我们的重要信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgxNjczNTRyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgxNjczNTRyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251218167354/en/</p>
<p>Phibro Animal Health Corporation</p>
<p>Glenn C. David</p>
<p>首席财务官</p>
<p>+1-201-329-7300</p>
<p>或</p>
<p>investor.relations@pahc.com</p>
<p>来源：Phibro Animal Health Corporation</p>

PAHC

<p>Phibro Animal Health Corporation 宣布将于 2026 年 7 月 1 日进行领导层变更。Jack Bendheim 将担任执行董事长，而 Daniel Bendheim 将担任首席执行官和总裁。此次变更支持 Phibro 的增长和战略方向。Jack Bendheim 将继续担任董事会主席，提供战略监督。Daniel Bendheim 拥有丰富的经验，旨在推动公司的战略和创新。董事会支持这一变更，以确保连续性和增长</p>

<p><strong>Jack Bendheim to Assume the Role of Executive Chairman; Daniel Bendheim Named Chief Executive Officer and President</strong></p>
<div class="lb-trans"><p><strong>杰克·本德海姆将担任执行董事长；丹尼尔·本德海姆被任命为首席执行官和总裁</strong></p>
</div><p>TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced a leadership transition that will support the Company’s continued growth and long-term strategic direction. At the end of this fiscal year, effective July 1, 2026, Jack Bendheim, current Chairman, Chief Executive Officer and President of Phibro will take on a new managerial role as Executive Chairman and Daniel (Dani) Bendheim will assume the role of Chief Executive Officer and President of Phibro. Jack Bendheim will continue to serve as the Chairman of the Board of Directors of the Company.</p>
<div class="lb-trans"><p>新泽西州提安克 --（商业新闻）-- 菲博动物健康公司（Nasdaq: PAHC）（“公司” 或 “菲博”）今天宣布了一项领导层变更，以支持公司的持续增长和长期战略方向。在本财年结束时，即 2026 年 7 月 1 日，现任菲博董事长、首席执行官和总裁的杰克·本德海姆将担任新的管理角色，成为执行董事长，而丹尼尔（丹尼）·本德海姆将担任菲博的首席执行官和总裁。杰克·本德海姆将继续担任公司董事会主席。</p>
</div><p>Jack Bendheim joined the Company in 1969 serving in various management and executive roles. He has served as the Company’s President since 1988 and was appointed Chief Executive Officer in March 2014. He has guided the Company through significant global expansion, portfolio growth and operational transformation. Under his leadership, Phibro has become one of the leaders in the animal health industry and strengthened its position as a trusted partner in animal health and nutrition, serving livestock producers and customers throughout the world.</p>
<div class="lb-trans"><p>杰克·本德海姆于 1969 年加入公司，担任过多个管理和执行职位。自 1988 年以来，他一直担任公司的总裁，并于 2014 年 3 月被任命为首席执行官。他引导公司经历了重大的全球扩张、产品组合增长和运营转型。在他的领导下，菲博已成为动物健康行业的领导者之一，并巩固了其作为动物健康和营养领域值得信赖的合作伙伴的地位，为全球的畜牧生产者和客户提供服务。</p>
</div><p>“As Phibro continues to evolve and expand, this is the right moment to transition leadership to guide the Company’s next chapter,” said Jack Bendheim. “Dani brings deep knowledge of our business, strong operational discipline and a global perspective that aligns with the future of our industry. I have full confidence in his ability to lead Phibro forward while maintaining the values, relationships and commitment to animal health that have defined our Company for decades.”</p>
<div class="lb-trans"><p>“随着菲博的不断发展和扩展，现在是过渡领导层以引导公司进入下一个篇章的合适时机，” 杰克·本德海姆说。“丹尼对我们的业务有深刻的了解，具备强大的运营纪律和全球视野，这与我们行业的未来相一致。我对他能够引领菲博向前发展，同时保持我们几十年来定义公司的价值观、关系和对动物健康的承诺充满信心。”</p>
</div><p>The Company’s full executive leadership team will remain in place and the Company’s Board of Directors has expressed its unanimous support for the transition and confidence in the leadership team’s ability to execute on the Company’s growth strategy.</p>
<div class="lb-trans"><p>公司的完整执行领导团队将继续留任，公司的董事会已表示对这一过渡的全力支持，并对领导团队执行公司增长战略的能力充满信心。</p>
</div><p>In his new role as Executive Chairman, Jack Bendheim will continue to provide strategic oversight, support Phibro’s long-term growth initiatives and work closely with the executive leadership team.</p>
<div class="lb-trans"><p>在担任执行董事长的新角色中，杰克·本德海姆将继续提供战略监督，支持菲博的长期增长计划，并与执行领导团队密切合作。</p>
</div><p>Dani Bendheim joined Phibro in 1997 and was appointed Vice President of Business Development in 2001, President of Performance Products in 2004 and Executive Vice President, Corporate Strategy in March 2014. Most recently, he has served as Chief Transformation Officer for the Company’s Phibro Forward initiative - an enterprise-wide program focused on driving efficiency, growth and cultural engagement that has played a key role in the Company’s recent growth. Dani Bendheim assumes the role of Chief Executive Officer and President having extensive experience across Phibro’s global operations and a proven track record of leadership within the Company. His appointment reflects Phibro’s disciplined succession planning and its commitment to continuity, innovation and growth.</p>
<div class="lb-trans"><p>丹尼·本德海姆于 1997 年加入菲博，并于 2001 年被任命为业务发展副总裁，2004 年成为性能产品总裁，并于 2014 年 3 月担任企业战略执行副总裁。最近，他担任公司的首席转型官，负责菲博前进计划——一个专注于推动效率、增长和文化参与的企业范围内的项目，在公司最近的增长中发挥了关键作用。丹尼·本德海姆在菲博的全球运营中拥有丰富的经验，并在公司内有着良好的领导记录，他的任命反映了菲博的有序接班计划及其对连续性、创新和增长的承诺。</p>
</div><p>“I am honored to take on this role and grateful for my father’s decades of leadership and guidance,” said Dani Bendheim. “Phibro is in the best position it has ever been, a customer-focused company with a strong foundation and commitment to innovation. I look forward to continuing to work with our global leadership team and our dedicated and committed employees worldwide, to advance our strategy, support our customers and build on the Company’s momentum.”</p>
<div class="lb-trans"><p>“我很荣幸能担任这个角色，并对我父亲几十年的领导和指导心怀感激，” 丹尼·本德海姆说。“菲博正处于历史上最好的位置，是一家以客户为中心的公司，拥有强大的基础和对创新的承诺。我期待继续与我们的全球领导团队以及我们在世界各地的敬业员工合作，推进我们的战略，支持我们的客户，并在公司的发展势头上继续前进。”</p>
</div><p><strong>About Phibro Animal Health Corporation</strong></p>
<div class="lb-trans"><p><strong>关于菲博动物健康公司</strong></p>
</div><p>Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.</p>
<div class="lb-trans"><p>菲博动物健康公司是一家领先的全球多元化动物健康和营养公司。我们努力成为与畜牧生产者、农民、兽医和养殖或照顾农场和伴侣动物的消费者之间值得信赖的合作伙伴，提供解决方案以帮助他们维护和增强动物的健康。有关更多信息，请访问 www.pahc.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>DISCLOSURE NOTICES</p>
<div class="lb-trans"><p>披露通知</p>
</div><p>Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.</p>
<div class="lb-trans"><p>前瞻性声明：本通讯包含前瞻性声明，这些声明受到风险和不确定性的影响。所有除历史或当前事实声明以外的声明均为前瞻性声明。前瞻性声明讨论了我们对财务状况、运营结果、计划、目标、未来表现和业务的当前期望和预测。您可以通过这些声明与历史或当前事实无关来识别前瞻性声明。这些声明可能包括诸如 “目标”、“预期”、“相信”、“估计”、“期望”、“预测”、“展望”、“潜力”、“项目”、“计划”、“打算”、“寻求”、“可能”、“可以”、“将”、“应该”、“能够”、“可能” 等词语及其否定形式，以及与未来运营或财务表现或其他事件的时间或性质相关的任何讨论中的其他类似词语和术语。这些声明并不保证未来的表现或行动。如果这些风险或不确定性中的一个或多个实现，或者管理层的基本假设被证明是错误的，实际结果可能与前瞻性声明所设想的有重大差异。前瞻性声明仅在作出声明的日期有效。菲博明确声明不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。有关风险、不确定性和其他事项的进一步列表和描述可以在我们的 10-Q 季度报告和 10-K 年度报告中找到，包括其中标题为 “前瞻性声明” 和 “风险因素” 的部分。这些文件及后续文件可在 www.sec.gov、www.pahc.com 在线获取，或应菲博的要求提供。</p>
</div><p>Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.</p>
<div class="lb-trans"><p>信息的互联网发布：我们定期在我们的网站 www.pahc.com 的 “投资者” 部分发布可能对投资者重要的信息。我们鼓励投资者和潜在投资者定期查阅我们的网站，以获取有关我们的重要信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgxNjczNTRyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251218167354r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218167354/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251218167354/en/</p>
</div><p>Phibro Animal Health Corporation</p>
<div class="lb-trans"><p>Phibro Animal Health Corporation</p>
</div><p>Glenn C. David</p>
<div class="lb-trans"><p>Glenn C. David</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>+1-201-329-7300</p>
<div class="lb-trans"><p>+1-201-329-7300</p>
</div><p>or</p>
<div class="lb-trans"><p>或</p>
</div><p>investor.relations@pahc.com</p>
<div class="lb-trans"><p>investor.relations@pahc.com</p>
</div><p>Source: Phibro Animal Health Corporation</p>
<div class="lb-trans"><p>来源：Phibro Animal Health Corporation</p>
</div>

Phibro Animal Health 公司宣布领导层变动 | PAHC 股票新闻